摘要： 心肌炎是一种由感染等多种因素引发的心肌炎症性疾病,其核心病理生理过程主要涉及病毒直接损伤与免疫介导的心肌损害。临床表现异质性强,诊断依赖于临床表现、试验室检验结果及心脏磁共振等检查的综合评估。治疗上以支持治疗和心力衰竭的标准管理为核心,针对性的抗病毒及免疫调节治疗目前缺乏高级别循证医学证据,疗效存在争议。预后差异显著,部分患者可完全康复,部分则可能进展为扩张型心肌病。因此,早期识别、急性期积极支持以及长期规范随访是改善预后的关键。
盛子洵, 向平. 心肌炎治疗现状及新进展[J]. 心血管病防治知识, 2026, 16(5): 138-144.
| [1] Kindermann I, Barth C, Mahfoud F, et al.Update on myocarditis[J]. Journal of the American College of Cardiology, 2012, 59(9): 779-792. [2] Fung R C M, Hon K L, Leung A K C. Acute Myocarditis in Children: An Overview of Treatment and Recent Patents[J]. Recent Patents on Inflammation & Allergy Drug Discovery, 2020, 14(2): 106-116. [3] Butts R J, Boyle G J, Deshpande S R, et al.Characteristics of Clinically Diagnosed Pediatric Myocarditis in a Contemporary Multi-Center Cohort[J]. Pediatric Cardiology, 2017, 38(6): 1175-1182. [4] Canter C E, Simpson K E.Diagnosis and treatment of myocarditis in children in the current era[J]. Circulation, 2014, 129(1): 115-128. [5] Leung T N, Hon K L, Leung A K.Group A Streptococcus disease in Hong Kong children: an overview[J]. Hong Kong Medical Journal=Xianggang Yi Xue Za Zhi, 2018, 24(6): 593-601. [6] Law Y M, Lal A K, Chen S, et al.Diagnosis and Management of Myocarditis in Children: A Scientific Statement From the American Heart Association[J]. Circulation, 2021, 144(6): e123-e135. [7] Wu L, Ong S, Talor M V, et al.Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy[J]. The Journal of Experimental Medicine, 2014, 211(7): 1449-1464. [8] Putschoegl A, Auerbach S. Diagnosis, Evaluation,Treatment of Myocarditis in Children[J]. Pediatric Clinics of North America, 2020, 67(5): 855-874. [9] Pollack A, Kontorovich A R, Fuster V, et al.Viral myocarditis--diagnosis, treatment options, and current controversies[J]. Nature Reviews. Cardiology, 2015, 12(11): 670-680. [10] Baughman K L.Diagnosis of myocarditis: death of Dallas criteria[J]. Circulation, 2006, 113(4): 593-595. [11] Ammirati E, Frigerio M, Adler E D, et al.Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document[J]. Circulation. Heart Failure, 2020, 13(11): e007405. [12] Chen J, Chen S, Li Z, et al.Role of electrocardiograms in assessment of severity and analysis of the characteristics of ST elevation in acute myocarditis: A two-centre study[J]. Experimental and Therapeutic Medicine, 2020, 20(5): 20. [13] Adegbala O, Olagoke O, Akintoye E, et al.Predictors, Burden, and the Impact of Arrhythmia on Patients Admitted for Acute Myocarditis[J]. The American Journal of Cardiology, 2019, 123(1): 139-144. [14] Nagai T, Inomata T, Kohno T, et al.JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis[J]. Circulation Journal: Official Journal of the Japanese Circulation Society, 2023, 87(5): 674-754. [15] Ogunbayo G O, Elayi S C, Ha L D, et al.Outcomes of Heart Block in Myocarditis: A Review of 31,760 Patients[J]. Heart, Lung & Circulation, 2019, 28(2): 272-276. [16] Ren Y, He Y, Hao Y, et al.Impact of low environmental temperatures on the global burden of myocarditis: insights from the 1990-2021 global burden of disease study[J]. BMC cardiovascular disorders, 2025, 25(1): 731. [17] Shao L, Ma A, Figtree G, et al.Combination Therapy With Coenzyme Q10 and Trimetazidine in Patients With Acute Viral Myocarditis[J]. Journal of Cardiovascular Pharmacology, 2016, 68(2): 150-154. [18] Amdani S M, Kim H S, Orvedahl A, et al. Successful treatment of fulminant neonatal enteroviral myocarditis in monochorionic diamniotic twins with cardiopulmonary support, intravenous immunoglobulin and pocapavir[J]. BMJ case reports, 2018, 2018: bcr2017224133, bcr-2017-224133. [19] Durak Aslan A, Havan M, Arga G, et al.Successfully Treated Adenovirus-Associated Fulminant Myocarditis by Cidofovir[J]. Turkish Archives of Pediatrics, 2025, 60(6): 683-684. [20] Tschöpe C, Van Linthout S, Klein O, et al.Mechanical Unloading by Fulminant Myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA Concepts[J]. Journal of Cardiovascular Translational Research, 2019, 12(2): 116-123. [21] Wang Y X, da Cunha V, Vincelette J, et al. Antiviral and myocyte protective effects of murine interferon-beta and-{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice[J]. American Journal of Physiology. Heart and Circulatory Physiology, 2007, 293(1): H69-76. [22] Kühl U, Pauschinger M, Schwimmbeck P L, et al.Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction[J]. Circulation, 2003, 107(22): 2793-2798. [23] Gran F, Dolader P, Juzga-Corrales D C, et al. Interferon-beta and corticosteroid therapy for parvovirus B19 myocarditis in children[J]. International Journal of Cardiology, 2025, 434: 133337. [24] Dickstein K, Cohen-Solal A, Filippatos G, et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)[J]. European Journal of Heart Failure, 2008, 10(10): 933-989. [25] Frea S, Pidello S, Volpe A, et al.Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure-bolus intermittent [26] Teerlink J R, Metra M, Felker G M, et al.Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study[J]. Lancet (London, England), 2009, 373(9673): 1429-1439. [27] Drucker N A, Colan S D, Lewis A B, et al.Gamma-globulin treatment of acute myocarditis in the pediatric population[J]. Circulation, 1994, 89(1): 252-257. [28] Lin M S, Tseng Y H, Chen M Y, et al.In-hospital and post-discharge outcomes of pediatric acute myocarditis underwent after high-dose steroid or intravenous immunoglobulin therapy[J]. BMC cardiovascular disorders, 2019, 19(1): 10. [29] Mason J W, O’Connell J B, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators[J]. The New England Journal of Medicine, 1995, 333(5): 269-275. [30] He C, Xu L, Zhang Z, et al.NT-proBNP serves as a prognostic marker for adverse outcomes in severe immune checkpoint inhibitor-associated myocarditis[J]. PeerJ, 2025, 13: e20020. [31] Cheng X, Long L, Li Y, et al.Prognostic risk factors and a survival prediction model for immune checkpoint inhibitor related myocarditis in patients with lung cancer: a multicenter study[J]. Scientific Reports, 2025, 15(1): 35514. [32] Merken J, Hazebroek M, Van Paassen P, et al.Immunosuppressive Therapy Improves Both Short-and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy[J]. Circulation. Heart Failure, 2018, 11(2): e004228. [33] Frustaci A, Russo M A, Chimenti C.Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study[J]. European Heart Journal, 2009, 30(16): 1995-2002. [34] Bhatt G C, Sankar J, Kushwaha K P.Use of intravenous immunoglobulin compared with standard therapy is associated with improved clinical outcomes in children with acute encephalitis syndrome complicated by myocarditis[J]. Pediatric Cardiology, 2012, 33(8): 1370-1376. [35] Gan A, Burke M, Yang E, et al.Successful Management of Oxacillin-Induced Eosinophilic Myocarditis and Review of the Literature[J]. JACC. Case reports, 2025, 30(31): 105297. [36] Cao Q, Ge Y, Wang T, et al.Dual-targeting exosome vaccine confers efficient protection against CVB3-induced myocarditis[J]. Nanomedicine: Nanotechnology, Biology, and Medicine, 2025, 70: 102865. [37] Zhang Y, Yue J, Wu B, et al.An RNAi Therapy That Attenuates Multi-Organ Viremia and Improves Animal Survival in a Lethal EMCV Challenge Model[J]. Viruses, 2025, 17(9): 1240. [38] Yin X, Wang D, Lyu J, et al.The Ubiquitin-Proteasome System: A Key Regulatory Hub in Myocarditis Leading to Dilated Cardiomyopathy[J]. Journal of Inflammation Research, 2025, 18: 13555-13574. [39] Zhang S, Gao W, Gao X, et al.Astragaloside VI attenuates mechanical stress-induced cardiac remodeling through piezo1-VDAC1 dependent endoplasmic reticulum unfolded protein response[J]. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 2025, 148: 157288. [40] Dai L, Duan Y, Xiong Q.From tumor immunotherapy to myocardial injury: A mechanistic discussion of immune checkpoint inhibitor-related myocarditis (Review)[J]. Molecular Medicine Reports, 2025, 32(6): 332. [41] Vockenhuber T, Baldinger L, Clausen J, et al.Successful Use of Ruxolitinib for Steroid-Refractory Immune Checkpoint Inhibitor-Associated Myocarditis[J]. JACC. Case reports, 2025, 30(35): 105543. [42] Kociol R D, Cooper L T, Fang J C, et al.Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association[J]. Circulation, 2020, 141(6): e69-e92. [43] Rajagopal S K, Almond C S, Laussen P C, et al.Extracorporeal membrane oxygenation for the support of infants, children, and young adults with acute myocarditis: a review of the Extracorporeal Life Support Organization registry[J]. Critical Care Medicine, 2010, 38(2): 382-387. [44] Thiele H, Zeymer U, Neumann F J, et al.Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial[J]. Lancet (London, England), 2013, 382(9905): 1638-1645. [45] Ouweneel D M, Eriksen E, Sjauw K D, et al.Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction[J]. Journal of the American College of Cardiology, 2017, 69(3): 278-287. [46] Seyfarth M, Sibbing D, Bauer I, et al.A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction[J]. Journal of the American College of Cardiology, 2008, 52(19): 1584-1588. [47] Šustić M, Jakljević T, Miovski Z, et al.Straightening Misfolded Microaxial Flow Pump in the Aorta Using a Snare Catheter[J]. JACC. Case reports, 2025, 30(30): 105218. [48] Schrage B, Becher P M, Bernhardt A, et al.Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study[J]. Circulation, 2020, 142(22): 2095-2106. [49] Garbern J C, Gauvreau K, Blume E D, et al.Is Myocarditis an Independent Risk Factor for Post-Transplant Mortality in Pediatric Heart Transplant Recipients?[J]. Circulation. Heart Failure, 2016, 9(1): e002328. [50] Peretto G, Sala S, Rizzo S, et al.Arrhythmias in myocarditis: State of the art[J]. Heart Rhythm, 2019, 16(5): 793-801. [51] Sachdeva S, Song X, Dham N, et al.Analysis of clinical parameters and cardiac magnetic resonance imaging as predictors of outcome in pediatric myocarditis[J]. The American Journal of Cardiology, 2015, 115(4): 499-504. [52] Fairweather D, Cooper L T, Blauwet L A.Sex and gender differences in myocarditis and dilated cardiomyopathy[J]. Current Problems in Cardiology, 2013, 38(1): 7-46. [53] Kindermann I, Kindermann M, Kandolf R, et al.Predictors of outcome in patients with suspected myocarditis[J]. Circulation, 2008, 118(6): 639-648. [54] Martino T A, Liu P, Sole M J.Viral infection and the pathogenesis of dilated cardiomyopathy[J]. Circulation Research, 1994, 74(2): 182-188. [55] Bowles N E, Rose M L, Taylor P, et al.End-stage dilated cardiomyopathy. Persistence of enterovirus RNA in myocardium at cardiac transplantation and lack of immune response[J]. Circulation, 1989, 80(5): 1128-1136. |
| [1] | 薛磊. HDL-C/TC、TyG指数及胰岛素抵抗指数与ACS合并糖尿病患者介入治疗后无复流的关系[J]. 心血管病防治知识, 2026, 16(6): 18-23. |
| [2] | 杨瑞霞. 护士主导的家属支持模式对冠心病介入术后双抗治疗依从性、自我管理水平及MACE发生率的影响[J]. 心血管病防治知识, 2026, 16(6): 68-71. |
| [3] | 王馨梅, 林圣英, 兰玲. 基于双向质量反馈的多维度康复护理在急性心肌梗死患者介入治疗后的应用[J]. 心血管病防治知识, 2026, 16(6): 76-79. |
| [4] | 邱红, 万瑞廷. 老年冠心病PCI术后心理健康现状及影响因素分析[J]. 心血管病防治知识, 2026, 16(5): 61-64. |
| [5] | 陈祺, 林圣斓. 有氧运动结合药物治疗对老年肥胖高血压患者夜间血压的影响[J]. 心血管病防治知识, 2026, 16(4): 24-27. |
| [6] | 张诗. 依从性促进理论指导下个体化护理在血液灌流联合血液透析治疗尿毒症合并高血压患者的效果[J]. 心血管病防治知识, 2026, 16(4): 89-92. |
| [7] | 邢晓丽, 杨波, 田维维. 丁苯酞氯化钠注射液联合双抗治疗急性非心源性轻型缺血性卒中的临床疗效[J]. 心血管病防治知识, 2026, 16(3): 3-7. |
| [8] | 汤玉探, 单婧妍. 老年急性心肌梗死患者经皮冠状动脉介入治疗后自我管理行为现状及影响因素模型的构建[J]. 心血管病防治知识, 2026, 16(3): 8-11. |
| [9] | 孙雅楠, 赵东晖, 鲁硕. TyG指数与依洛尤单抗治疗急性冠脉综合征患者PCI术后不良事件的相关性[J]. 心血管病防治知识, 2026, 16(3): 12-15. |
| [10] | 张燕妮, 詹鑫亮, 熊苗. CTEPH患者抗凝治疗前后核素肺通气/灌注定量参数变化及与右心室功能的关联性[J]. 心血管病防治知识, 2026, 16(3): 31-36. |
| [11] | 徐超成, 罗俭权, 陶珊花, 吕敬雄. 血栓弹力图联合D-二聚体在房颤患者抗凝管理中的价值研究[J]. 心血管病防治知识, 2026, 16(1): 22-25. |
| [12] | 谢仁兵, 石红霞, 张鹏. ABC评分及SAMe-TT2R2评分对非瓣膜性心房颤动合并冠心病患者抗凝后出血风险的评估价值[J]. 心血管病防治知识, 2026, 16(1): 68-71. |
| [13] | 林菁. 冠状动脉造影与光学相干断层成像技术联合应用于STEMI患者介入治疗的效果[J]. 心血管病防治知识, 2025, 15(9): 24-27. |
| [14] | 刘丹. 群组管理模式对心脏瓣膜置换术后患者华法林抗凝治疗依从性、自护能力及不良事件的影响[J]. 心血管病防治知识, 2025, 15(9): 124-126. |
| [15] | 曹海平. 急性心肌梗死患者急诊介入治疗后心肌微循环障碍的相关因素及干预措施[J]. 心血管病防治知识, 2025, 15(8): 28-32. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
